Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marshall Hill

Ophthalmology Fort Stewart, GA Medical Doctor

NPI 1447610100 CMS profile 4222948

1061 Harmon Ave, Fort Stewart, GA 31314

Open in the dashboard

General payments

$1,948

26 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marshall Hill of Fort Stewart, GA is reported in the CMS Open Payments database as having received $1,948 across 26 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $272 8
2023 General $187 1
2019 General $1,489 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marshall Hill
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Marshall Hill were reported at $272. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Marshall Hill Ophthalmology median Middle half National median
2019 $1,489 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $0 $266 $100–$678 $149
2023 $187 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $272 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb, a division of Bausch Health US, LLC $1,424 16 payments
  2. Carl Zeiss Meditec USA, Inc. $187 1 payment
  3. Alcon Vision LLC $164 3 payments
  4. Carl Zeiss Meditec, Inc. $65 1 payment
  5. Oyster Point Pharma, Inc. $37 2 payments
  6. Harrow Eye, LLC $31 1 payment
  7. Dompe US, Inc. $21 1 payment
  8. RxSight Inc $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $994 21 payments
  2. Travel and Lodging $954 5 payments
Products named General payments · program years 2019–2025
  1. ENVISTA $1,424 16 payments
  2. AKREOS AO $1,424 16 payments
  3. STELLARIS PC $1,424 16 payments
  4. CRYSTALENS $1,424 16 payments
  5. TRULIGN TORIC $1,424 16 payments
  6. VisuMax $187 1 payment
  7. Clareon PanOptix Pro $156 2 payments
  8. TYRVAYA $37 2 payments
  9. VEVYE $31 1 payment
  10. OXERVATE $21 1 payment
  11. Other $105 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

513

Median for Ophthalmology: 891

Drug cost

$13,281

Median for Ophthalmology: $68,233

Branded share of claims

23%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorometholone Generic 63 $4,466
Prednisolone Acetate Generic 113 $4,058
Ketorolac Tromethamine Generic 66 $1,664
Latanoprost Generic 91 $696
Brimonidine Tartrate Generic 17 $416
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 23 $371
Timolol Maleate Generic 33 $360
Polymyxin B Sul-Trimethoprim Polymyxin B Sulf/Trimethoprim Brand 43 $359
Erythromycin Erythromycin Base Brand 20 $232
Moxifloxacin Moxifloxacin Hcl Brand 12 $224

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$90,227

Medicare's payments for the services billed

Medicare patients

604

Average age 76

Services billed

942

370 women, 234 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 35%
Ischemic heart disease 28%
Chronic kidney disease 22%
Osteoporosis 16%
Atrial fibrillation 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record